Clinical Characteristics and Outcomes of Children With SARS-CoV-2 Infection During the Delta and Omicron Variant-Dominant Periods in Korea.
Adolescent
COVID-19
Child
SARS-CoV-2 Delta Variant
SARS-CoV-2 Omicron Variant
SARS-CoV-2 Variants
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
06 Mar 2023
06 Mar 2023
Historique:
received:
13
09
2022
accepted:
06
12
2022
entrez:
7
3
2023
pubmed:
8
3
2023
medline:
9
3
2023
Statut:
epublish
Résumé
Data on the clinical characteristics of pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infection are limited. We aimed to evaluate the clinical features and outcomes of children with SARS-CoV-2 infection before and after omicron variant dominance in Korea. A multicenter retrospective cohort study was conducted in hospitalized patients aged ≤ 18 years with laboratory-confirmed SARS-CoV-2 infection at five university hospitals in South Korea. The study periods were divided into the delta (from August 23, 2021 to January 2, 2022) and omicron (from January 30 to March 31, 2022). In total, 612 hospitalized patients were identified (211, delta; 401, omicron). During the omicron and delta periods, the proportions of individuals with serious illness (moderate, severe, and critical severity) were 21.2% and 11.8%, respectively ( Compared with the delta period, the proportions of young children and patients with complex comorbidities were higher during the omicron period in Korea. Patients with complex chronic diseases, especially neurologic diseases, had a high risk of severe coronavirus disease 2019 in the two distinct variant-dominant periods.
Sections du résumé
BACKGROUND
BACKGROUND
Data on the clinical characteristics of pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infection are limited. We aimed to evaluate the clinical features and outcomes of children with SARS-CoV-2 infection before and after omicron variant dominance in Korea.
METHODS
METHODS
A multicenter retrospective cohort study was conducted in hospitalized patients aged ≤ 18 years with laboratory-confirmed SARS-CoV-2 infection at five university hospitals in South Korea. The study periods were divided into the delta (from August 23, 2021 to January 2, 2022) and omicron (from January 30 to March 31, 2022).
RESULTS
RESULTS
In total, 612 hospitalized patients were identified (211, delta; 401, omicron). During the omicron and delta periods, the proportions of individuals with serious illness (moderate, severe, and critical severity) were 21.2% and 11.8%, respectively (
CONCLUSION
CONCLUSIONS
Compared with the delta period, the proportions of young children and patients with complex comorbidities were higher during the omicron period in Korea. Patients with complex chronic diseases, especially neurologic diseases, had a high risk of severe coronavirus disease 2019 in the two distinct variant-dominant periods.
Identifiants
pubmed: 36880106
pii: 38.e65
doi: 10.3346/jkms.2023.38.e65
pmc: PMC9988433
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e65Subventions
Organisme : Korea Disease Control and Prevention Agency
ID : 20211209C4A
Pays : Korea
Informations de copyright
© 2023 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
JAMA Pediatr. 2022 Aug 1;176(8):819-821
pubmed: 35426941
Pediatr Infect Dis J. 2020 Sep;39(9):789-793
pubmed: 32282657
J Korean Med Sci. 2022 Oct 31;37(42):e303
pubmed: 36325607
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):271-278
pubmed: 35176003
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-152
pubmed: 35085225
J Pediatric Infect Dis Soc. 2021 Nov 11;10(10):951-957
pubmed: 34245307
Emerg Infect Dis. 2022 Apr;28(4):898-900
pubmed: 35171760
Pediatrics. 2014 Jun;133(6):e1647-54
pubmed: 24819580
Lancet Child Adolesc Health. 2022 May;6(5):294-302
pubmed: 35189083
Pediatrics. 2021 Dec 22;149(1):
pubmed: 34935038
Acta Paediatr. 2022 May;111(5):1023-1026
pubmed: 35098577
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):429-436
pubmed: 35298458
Clin Infect Dis. 2022 Aug 24;75(1):e361-e367
pubmed: 35404391
Pediatrics. 2022 Apr 1;149(4):
pubmed: 35322270
N Engl J Med. 2022 May 19;386(20):1899-1909
pubmed: 35353976
JAMA Netw Open. 2022 Feb 1;5(2):e2143151
pubmed: 35133437
Clin Infect Dis. 2017 Aug 15;65(4):653-660
pubmed: 29017268
Acad Pediatr. 2018 Jul;18(5):577-580
pubmed: 29496546
J Pediatr. 2016 Mar;170:135-41.e1-5
pubmed: 26687576
Pediatr Infect Dis J. 2022 May 1;41(5):e249-e251
pubmed: 35333818
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
MMWR Morb Mortal Wkly Rep. 2022 Apr 22;71(16):574-581
pubmed: 35446827
JAMA Pediatr. 2022 Aug 1;176(8):811-813
pubmed: 35363246
Pediatr Infect Dis J. 2022 May 1;41(5):e249
pubmed: 35185142
Pediatrics. 2022 Jun 1;149(6):
pubmed: 35257175
Korean J Pediatr. 2018 May;61(5):135-149
pubmed: 29853938